293 related articles for article (PubMed ID: 15062762)
1. Comparison of the ADVIA Centaur and Abbott AxSYM immunoassay systems for a routine diagnostic virology laboratory.
Taylor P; Pickard G; Gammie A; Atkins M
J Clin Virol; 2004 Apr; 30 Suppl 1():S11-5. PubMed ID: 15062762
[TBL] [Abstract][Full Text] [Related]
2. Performance of hepatitis B assays on the Bayer ADVIA Centaur Immunoassay System.
van Helden J; Denoyel G; Karwowska S; Reamer R; Schmalz J; Wright T; Preisel-Simmons B
Clin Lab; 2004; 50(1-2):63-73. PubMed ID: 15000222
[TBL] [Abstract][Full Text] [Related]
3. European performance evaluations of the ADVIA Centaur infectious disease assays: requirements for performance evaluation according to the European directive on in vitro diagnostics.
Dati F; Denoyel G; van Helden J
J Clin Virol; 2004 Apr; 30 Suppl 1():S6-10. PubMed ID: 15062761
[TBL] [Abstract][Full Text] [Related]
4. The ADVIA Centaur infectious disease assays: a technical review.
Dwyer R
J Clin Virol; 2004 Apr; 30 Suppl 1():S1-5. PubMed ID: 15062760
[TBL] [Abstract][Full Text] [Related]
5. Performance evaluation of the ADVIA Centaur anti-HBe and HBeAg assays.
van Helden J; Cornely C; Dati F; Levy HR; Bal T; Seeger M; Wright T; Baker L
J Clin Virol; 2008 Oct; 43(2):169-75. PubMed ID: 18635392
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of two chemiluminescent immunoassays of ADVIA Centaur for hepatitis B serology markers.
Chen D; Kaplan L; Liu Q
Clin Chim Acta; 2005 May; 355(1-2):41-5. PubMed ID: 15820476
[TBL] [Abstract][Full Text] [Related]
7. Experience with the IVDD performance evaluations of the ADVIA Centaur infectious disease assays.
van Helden J; Denoyel GA
J Clin Virol; 2004 Apr; 30 Suppl 1():S16-8. PubMed ID: 15062763
[No Abstract] [Full Text] [Related]
8. Comparison of the automated AxSYM and ADVIA centaur immunoassays for homocysteine determination.
Haltmayer M; Mueller T; Gegenhuber A; Poelz W
Clin Lab; 2004; 50(3-4):175-80. PubMed ID: 15074472
[TBL] [Abstract][Full Text] [Related]
9. Performance of a new HIV 1/O/2 assay on the Bayer ADVIA Centaur immunoassay system.
van Helden J; Denoyel G; Freeman J; Preisel-Simmons B
Clin Lab; 2004; 50(1-2):83-90. PubMed ID: 15000224
[TBL] [Abstract][Full Text] [Related]
10. Performance of a new hepatitis C assay on the Bayer ADVIA Centaur Immunoassay System.
Denoyel G; van Helden J; Bauer R; Preisel-Simmons B
Clin Lab; 2004; 50(1-2):75-82. PubMed ID: 15000223
[TBL] [Abstract][Full Text] [Related]
11. The ADVIA Centaur immunoassay system--designed for infectious disease testing.
Okrongly D
J Clin Virol; 2004 Apr; 30 Suppl 1():S19-22. PubMed ID: 15062764
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the technical and clinical performance of the Elecsys HBsAg II assay with the Architect, AxSym, and Advia Centaur HBsAg screening assays.
Louisirirotchanakul S; Khupulsup K; Akraekthalin S; Chan KP; Saw S; Aw TC; Cho DH; Shin MG; Lim J
J Med Virol; 2010 May; 82(5):755-62. PubMed ID: 20336717
[TBL] [Abstract][Full Text] [Related]
13. Laboratory evaluation of the UniCel DxI 800 analyser (Beckman Coulter) for detecting HBV and HCV serological markers.
Miedouge M; Legrand-Abravanel F; Lalanne C; Saune K; Izopet J
J Clin Virol; 2009 Feb; 44(2):134-7. PubMed ID: 19110466
[TBL] [Abstract][Full Text] [Related]
14. An update on laboratory productivity with infectious disease assays on the Bayer ADVIA Centaur Immunoassay System.
Dati F
Clin Lab; 2004; 50(1-2):53-61. PubMed ID: 15000221
[TBL] [Abstract][Full Text] [Related]
15. Detection of antibodies to hepatitis C virus: false-negative results in an automated chemiluminescent microparticle immunoassay (ARCHITECT Anti-HCV) compared to a microparticle enzyme immunoassay (AxSYM HCV Version 3.0).
Myrmel H; Navaratnam V; Asjø B
J Clin Virol; 2005 Nov; 34(3):211-5; discussion 216-8. PubMed ID: 16112611
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the new ARCHITECT anti-HCV screening test under routine laboratory conditions.
Berger A; Rabenau H; Allwinn R; Doerr HW
J Clin Virol; 2008 Oct; 43(2):158-61. PubMed ID: 18635393
[TBL] [Abstract][Full Text] [Related]
17. Detection of HBsAg mutants in a population with a low prevalence of hepatitis B virus infection.
Gibb R; Nimmo GR; O'Loughlin P; Lowe P; Drummond D
J Med Virol; 2007 Apr; 79(4):351-5. PubMed ID: 17311336
[TBL] [Abstract][Full Text] [Related]
18. Detection of antibodies to hepatitis B core antigen using the Abbott ARCHITECT anti-HBc assay: analysis of borderline reactive sera.
Ollier L; Laffont C; Kechkekian A; Doglio A; Giordanengo V
J Virol Methods; 2008 Dec; 154(1-2):206-9. PubMed ID: 18848582
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of three commercially available hepatitis C virus antibody detection assays under the conditions of a clinical virology laboratory.
Zachary P; Ullmann M; Djeddi S; Meyer N; Wendling MJ; Schvoerer E; Stoll-Keller F; Gut JP
J Clin Virol; 2005 Nov; 34(3):207-10; discussion 216-8. PubMed ID: 16122975
[TBL] [Abstract][Full Text] [Related]
20. [Hepatitis C virus screening: performances characteristics of a commercial automated chemiluminescent microparticle immunoassay (CMIA-ARCHITECT anti-HCV)].
Petitjean Lecherbonnier J; Gouarin S; Dina J; Vabret A; Freymuth F
Pathol Biol (Paris); 2007 Dec; 55(10):512-20. PubMed ID: 17959324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
